Abacus Medicine is a leading supplier of original prescription medicine in Europe based on the core principle of the free movement of goods in the EU’s single market. The Company’s overall vision is to support better healthcare through better access to medicine. This is done by supplying medicine at more affordable prices in order to reduce healthcare costs which is Abacus Medicine’s overall contribution to society. Many of the products are expensive, life-critical medicines which are offered at lower prices through Abacus Medicine’s strong network.
The Company was founded in 2004 by Flemming Wagner and his father and is headquartered in Copenhagen, Denmark. Since inception it has grown into a Pan-European business with operations in +12 countries and 750 employees. As Abacus Medicine grows, so does the social impact and the Company recognizes its obligation to stakeholders and the wider society. The growth of the business stems from a continuous investment in new markets and increasing the number of product licenses for the medicines distributed. This approach is supported by second-to-none IT-systems for analyzing large data sets in real time making the Company frontrunners in the industry.
Besides the current core business, the Company is also tapping into the global market for pharmaceutical services including supply for clinical trials, non-licensed medicine and managed access programs through the brand name Aposave.